Thrombospondin (TSP), a 450-kD multifunctional glycoprotein with a broad tissue distribution, is secreted upon platelet stimulation, binds to the activated platelet surface, and supports platelet aggregation. We have identified and isolated an 88-kD membrane glycoprotein present in platelets, endothelial cells, monocytes, and a variety of human tumor cell lines that is the membrane binding site for TSP. Endogenous platelet TSP binding to thrombin-and ionophore-stimulated human platelets was inhibited in the presence of the monoclonal antibody OKM5. TSP binding to C32 melanoma cells and HT1080 fibrosarcoma cells was specific and also inhibitable with OKM5 Mab. Cell labeling followed by specific immnunoprecipitation demonstrated biosynthesis of a single 88-kD glycoprotein. Binding of TSP to the isolated membrane protein was specific and saturable. These studies identify an 88-kD membrane glycoprotein that reacts with the monoclonal antibody, OKM5, and may function as the cellular TSP receptor.
Introduction
Adhesive macromolecules play a central role in biology. By mediating cell-cell and cell-substrate interactions, they provide a framework upon which cell migration and morphogenesis occur during development (1, 2) . Adhesive phenomena are also necessary for normal hemostasis in the adult organism (3) and play a role in the metastatic behavior of certain tumors (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Although some adhesive molecules are intrinsic to the cell membrane, most are ligands for cellular receptors (14) (15) (16) (17) (18) (19) .
Platelet aggregation is a useful paradigm for characterizing cell adhesion phenomena. In vivo endothelial cell damage or denudation results in platelet adhesion with subsequent degranulation and the recruitment of additional platelets to form a plug. Platelet alpha granules contain numerous adhesive proteins, including von Willebrand factor, fibronectin, fibrinogen, and thrombospondin (TSP),' that are secreted upon platelet stimulation, bind to the platelet membrane, and mediate aggregation (20) (21) (22) (23) (24) (25) (26) . Fibrinogen links aggregating platelets by binding to the glycoprotein IIb/IIIa complex (GPIIb/IIIa) on opposing membranes (27). Von Willebrand factor and fibronectin share the capacity to bind to GPIIb/llIa and have in common a four amino acid cellular binding domain, Arg-Gly-Asp-Ser (28) (29) (30) (31) (32) (33) (34) (35) (36) . The GPIIb/IIIa complex has recently been identified in a variety of cells other than platelets, including endothelial cells (37) , smooth muscle cells, and fibroblasts (38) . Thus, this receptor complex and family ofadhesive proteins are likely to have broad biological importance. Thrombospondin, a major alpha granule glycoprotein (39) (40) (41) (42) (43) , differs from this family of proteins in that binding to the platelet surface does not appear to be mediated by GPIIb/ IIIa. Binding of TSP occurs normally on platelets from patients with Glanzmann's thrombasthenia-an inherited deficiency of platelet GPIIb/IIIa (44, 45). Thus, a separate receptor for TSP must exist.
TSP is an adhesive 450-kD multifunctional glycoprotein composed ofthree identical disulfide-linked chains (46) (47) (48) . TSP has a broad tissue distribution and is synthesized by endothelial cells (49, 50) , fibroblasts (51) , smooth muscle cells (52) , alveolar pneumocytes (53) , monocytes (54) , and neuroglial cells (55) and is incorporated into the matrix of growing cells (51, 56) . TSP is known to bind heparin (39, 41) , fibrinogen (57) , fibronectin (58, 59), histidine-rich glycoprotein (60) , collagen (61) , and plasminogen (62) . It has lectinlike properties (63) and is necessary for irreversible platelet aggregation (64) . TSP has also recently been reported to mediate the adherence to endothelium of red cells parasitized with Plasmodium falciparum (65) .
A monoclonal antibody (Mab), OKM5 (Ortho Diagnostic Systems Inc., Raritan, NJ), is reactive with platelets, endothelial cells, and monocytes (66, 67) . It identifies an 88-kD glycoprotein, and has recently been found to inhibit the cytoadherence of parasitized red cells to endothelial cell monolayers and the human melanoma cell line C32 (68) . These observations raise the possibility that the antigen identified by OKM5 Mab is the cellular TSP receptor.
We report the isolation ofan 88-kD membrane glycoprotein reactive with OKM5 Mab that binds TSP and may function as the cellular receptor for TSP. ulated human platelets was measured with '25I-anti TSP Fab. Plateletrich plasma (0.5 ml) was incubated with '25I-anti TSP Fab 4,000 cpm/ ,g and 10 gg/ml OKM5 Mab or a control anti-platelet monoclonal. Ionophore A23 187 (10 Mg/ml) was added for 2 min without stirring and the platelets were centrifuged for 8 min through silicone oil as previously described (64) . Bound radioactivity was quantified with an Isodyne gamma counter (Searle, Amsterdam, Netherlands), and inducible TSP expression was calculated as the difference between counts obtained with resting and stimulated platelets. Thrombin-inducible TSP expression was measured similarly with gel-filtered human platelets. Thrombin (final concentration, 1 U/ml) was added to platelets incubated with '25I-anti TSP Fab in the presence or absence ofOKM5 Mab (final concentration, 10 Mg/ml) without stirring for I min. Platelet pellets were obtained and counted as described above, and the difference between resting and stimulated bound radioactivity expressed as thrombin-inducible TSP.
The effect of OKM5 Mab (final concentration, 10 Ag/ml) on -251 TSP binding to HT1080 cells was examined in suspension cultures. HT1080 cells grown in MEM with 10% FCS were centrifuged and resuspended in serum-free MEM at a concentration of 106 cells/ml. Triplicate 0. 1-ml aliquots were incubated at 40C with 251I-TSP (16,000 cpm/ pmol) over a range of concentrations. At 2 h, the cells were centrifuged through silicone oil as described previously, and bound radioactivity was counted. The effect of polyclonal rabbit anti-glycoprotein (GP) IV antibody on TSP binding was also examined at the 100 ,g/ml TSP point. Data were subjected to analysis with a modification ofthe Ligand program (73, 74) .
The effect of OKM5 Mab (final concentration, 10 ,ug/ml) on 12sI1 TSP binding to C32 melanoma cells was examined over a range of TSP concentrations at 4°C for 2 h. Cells grown in culture flasks were resuspended in Hepes buffer containing 0.02% EDTA and then resuspended in MEM for the binding studies that were performed in triplicate. At 2 h, the cells were centrifuged through silicone oil and the radioactivity of the pellets was counted. The time course of binding was examined similarly at 4°C at 200 ug/ml TSP. Binding to monolayers grown in 24-well culture plates was performed similarly in MEM over a range of TSP concentrations at 4°C. At 2 h incubation, the wells were gently washed thrice with MEM and the cells were solubilized with 1% Triton X-100 in phosphate buffered saline (PBS), pH 7.4.
Isolation ofthe membrane binding site. Isolation of the 88-kD glycoprotein receptor from C32 melanoma cells and from human platelets was achieved with immunoaffinity column chromatography using an OKM5 Mab-Affigel 10 column. Cells were solubilized in PBS, pH 7.4, with 1% Triton X-100 in the presence of protease inhibitors. Following extensive washing, bound antigen was eluted from the column with 0.2 M glycine, pH 2.5, dialyzed against PBS, pH 7.4, and electrophoresed in a 7.5% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel (75) . The material was electrophoretically transferred to nitrocellulose paper and incubated with purified TSP (50 Mg/ml) in PBS, pH 7.4, with 0.05% Tween, 2 mM CaC12, 2 mM MgCl2, and 1% bovine serum albumin. Following washing in several changes of buffer, the nitrocellulose was probed with colloidal gold-labeled goat anti-rabbit antibody and developed with Auroprobe (Janssen Life Sciences Products, Piscataway, NJ). Western blotting of the immunoisolated material was performed by incubating with rabbit anti-GPIV IgG (50 Mg/ml), monospecific anti-GPV antisera (1:50 dilution), or normal rabbit antisera. Following extensive washing, detection was completed with peroxidase-conjugated goat antirabbit IgG and the colorimetric substrate 4-chloro-1-napthol. Two-dimensional gel electrophoresis of the immunoisolated material was performed using a modification of the Q'Farrel method as previously described (55) .
Biosynthetic labeling of the membrane binding site. C32 cell cultures grown in MEM with 10% FCS were labeled with 3H-mannose, 3H-fucose, 3H-galactosamine, or 3H-glucosamine for 24 h (0.5 mCi/ml) and solubilized in PBS, pH 7.4, with 1% Triton X. OKM5 Mab bound to Affigel 10 beads was used to immunoprecipitate antigen. Following extensive washing, the beads were boiled in 0.12 M Tris, pH 6.8, 2% SDS, 5% glycerol, 2.5% dithiothreitol, electrophoresed in a 7.5% SDS-PAGE gel, and autoradiography was performed.
TSP binding to the purified membrane binding site. The specificity ofbinding ofTSP to the membrane protein was examined using purified material in enzyme-linked immunosorbent assay studies. TSP or albumin (4 Mg/ml) were bound to the bottom of microtitre wells as previously described (62, 76) . Purified OKM5 antigen (4 Ag/ml) in PBS, Tween 0.05%, pH 7.4, was incubated in the wells for 90 min at 370C. Wells were washed three times in buffer, and OKM5 Mab (2 Mg/ml) was added to detect bound receptor. After additional washes, goat anti-mouse antibody conjugated to alkaline phosphatase was added and the bound OKM5 was quantified by the addition of the colorimetric substrate pnitrophenyl phosphate.
The affinity ofTSP for the isolated membrane protein was examined in binding studies using OKM5 antigen immobilized in microtitre wells. Immobilized OKM5 antigen was incubated with TSP or albumin in concentrations up to 400 Mg/ml, and binding was quantified using alkaline phosphatase conjugated second antibody and colorimetric substrate. Binding was examined in the presence of anti-TSP monoclonals C6.7 (500 ,ug/ml), 1 1.4 (100 gg/ml), or 45.2 (100 Mg/ml). Binding was also examined in the presence ofthe tetrapeptide Arg-Gly-Asp-Ser (0.12 mM and 1.2 mM) or 5 mM ethylene diamino tetra acetic acid. In an additional test of specificity, preincubation of the immobilized membrane binding site with OKM5 Mab (10 ug/ml) was done in control experiments before the addition of TSP.
Results
OKM5 Mab inhibits endogenous TSP binding to the platelet surface. Upon platelet stimulation, TSP is released from alpha granules and binds to the platelet surface (77) . Recent studies have demonstrated TSP binding to resting as well as stimulated platelets (44). To examine the expression on the platelet surface of endogenous platelet TSP, we measured the binding of 1251I labeled affinity-purified monospecific rabbit anti-TSP Fab to thrombin-and ionophore-stimulated platelets. Gel-filtered human platelets were stimulated with 1 U/ml thrombin for 2 min in the presence of '25I-anti TSP Fab and with either OKM5 Mab (10 ug/ml) or a control anti-platelet Mab (Fig. 1) . Thrombin-inducible TSP expression was completely inhibited in the presence of OKM5 Mab. The control anti-platelet Mab had no effect on TSP expression. Inhibition of TSP expression was not due to inhibition of release or aggregation, because in the presence of OKM5, thrombin aggregation was normal by aggregometry. In addition, platelet stimulation with the ionophore A23187 yielded similar results (Fig. 1) Mab. Binding was also inhibited by 50 ,g/ml polyclonal rabbit anti-GPIV antibody (Fig. 2) .
The human melanoma cell line, C32, has been used for studies on the cytoadherence of Plasmodium falciparum par- ,gg/ml OKM5 (Fig. 3) . Similar results were obtained with C32 cell monolayers. The time course of binding was examined at 4VC and a TSP concentration of 200 Mg/ml (Fig. 4) Isolation ofthe membrane TSP binding site. Using an OKM5 Mab affinity column, the binding site was isolated from C32 melanoma cells and platelets and electrophoresed in a 7.5% SDS-PAGE gel. The silver-stained gel is shown in Fig. 5 . Lane I is the protein immunoisolated from human platelets; lane 2 is derived from C32 melanoma cells. A single major band that migrates with an apparent molecular weight of 88 kD is present in both lanes. In two dimensional O'Farrel gels, the 88-kD material had an isoelectric point (pl) of 4.5-5.5 (not shown), consistent with previously published data on GPIV (79) .
Biosynthetic labeling ofthe binding site. To demonstrate endogenous synthesis of the OKM5 antigen, immunoprecipitation with OKM5 Mab-sepharose was used to purify an 88-kD glycoprotein from 3H-mannose, -fucose, -glucosamine, or -galactosamine-labeled C32 cells. Fig. 6 tibody confirmed reactivity specifically with the 88-kD material (lane 2). A nonspecific band of apparent Mr of 200 kD was present in both experimental as well as control blots with normal rabbit antisera. Immunoblots using a specific anti-GPV antisera were negative; as were ligand blots using 1251-labeled thrombin (data not shown).
To further examine the specificity of TSP binding to the OKM5 Mab antigen, several studies were performed with the purified material in ELISA binding experiments. TSP or albumin (4 Ag/ml) were coated on microtitre wells and binding of the purified OKM5 antigen was quantified with OKM5 Mab followed by alkaline phosphatase conjugated goat anti-mouse IgG (Fig. 8) . Binding of OKM5 antigen to immobilized TSP was more than 10-fold greater than that observed with immobilized albumin. These results show specific binding of the OKM5 antigen to TSP and exclude the possibility that the observed binding of TSP was due to a minor contaminant present in the preparation.
To define the characteristics of TSP binding to the purified receptor in an isolated system, microtitre wells with immobilized OKM5 antigen were incubated with TSP or albumin in concentrations up to 400 nM. Binding was quantified using alkaline phosphatase conjugated second antibodies followed by colorimetric substrate (Fig. 9) . Preincubation of the immobilized antigen with OKM5 Mab in similar experiments reduced TSP binding by one half. The apparent Kd ofthe receptor-TSP binding in this system was -50 nM. Albumin binding was not significant. Binding was inhibited in the presence of EDTA but 1 2 3 4 5 Figure 6 . Biosynthetic radiolabeling of OKM5 antigen. C32 melanoma cells were radiolabeled with 3H-mannose, -fucose, -galactosamine, or -glucosamine (0.5 mCi/ ml) for 24 h and OKM5 antigen was immunoprecipitated using OKM5 Mab coupled to Affigel 10 beads. Autoradiography reveals the presence of a single molecular weight species of 88 kD. was not inhibitable by the tetrapeptide Arg-Gly-Asp-Ser (Fig. 10) .
To further examine the specificity of binding, TSP binding was examined in the presence of monoclonal anti-TSP antibodies. C6.7 (500 ,g/ml), an anti-TSP monoclonal that inhibits the secretion-dependent phase of platelet aggregation (70) partially blocked TSP binding. Two anti-TSP monoclonals, that have no effect of platelet aggregation, 11.4 and 45.2 (100 Alg/ ml), completely blocked TSP binding to the immobilized receptor (data not shown). Thus, TSP binding to GPIV appears to be mediated by a domain or domains that are recognized by these antibodies.
Discussion
We have identified and isolated an 88-kD glycoprotein, present on platelets, endothelial cells, monocytes, and a variety ofhuman tumor 88-kD glycoprotein. The isolated protein bound TSP in a specific and saturable manner with an apparent Kd on plastic coated surfaces of 50 nM.
Recently, OKM5 Mab has been reported to identify an antigen on platelets that reacts with antisera to a 90-kD major surface glycoprotein referred to as GPIV (80) or GPIIIb by other nomenclature (79) . The material we immunoisolated with OKM5 Mab likewise reacts with anti-GPIV antibody, and TSP binding to cells was inhibited by the polyclonal antibody, thus supporting the conclusion that GPIV functions on the platelet surface and the two cell lines studied, as the membrane TSP binding site. GPIV is increased in platelets from patients with myeloproliferative syndromes, and it is interesting to note that yields of TSP receptor from platelets of such patients were several-fold higher than yields from normal donor platelets (A. Asch, personal observation). Another platelet membrane glycoprotein of similar molecular weight is GPV. GPV migrates with a molecular weight of 82 kD and has a pI of 7-8 (72) . GPV binds thrombin and is itself a thrombin substrate-being cleaved by thrombin to 70 kD (72) . To exclude the possibility that the receptor we isolated was GPV we examined the behavior of the immunoisolated material in two dimensional O'Farrel gels. The 88 kD material we isolated migrated with a pI range of 4.5-5.5. In Western blots, the material was nonreactive with monospecific anti-GPV antisera. Thrombin did not bind to the immunoiso- Figure 10 . Effect of EDTA and the tetrapeptide Arg-GlyAsp-Ser (RGDS) on TSP binding to the purified receptor. Purified OKM5 antigen (4 Ag/ml) was coated on the bottom of plastic microtiter wells, and the binding of purified TSP (50 ;g/ml) was examined in the presence of 2 The demonstration of specific and saturable TSP binding to C32 melanoma cells and to the fibrosarcoma cell line HT1080 raises the possibility that TSP localization on the cell surface may be an important component in the malignant phenotype ofthese cells. The mechanism by which malignant cells give rise to a gross metastasis has been described as a multistep process requiring detachment of a viable cell from the primary tumor mass into the circulation, survival within the circulation, adhesion to and migration through the endothelium and subendothelium of the target tissue, and successful growth in the new environment (82) . The factors that mediate these steps are not well known but several intriguing possibilities exist. Some data have been provided that implicate platelet-tumor cell interactions in the process oftumor cell metastasis, and in some murine models, antiplatelet agents inhibit the development of metastatic lesions (83) . The platelet-TSP-tumor cell aggregate may serve as a vehicle for efficient transport through the circulation. Alternatively, endogenous TSP production by tumor cell lines such as HT1080 (A. Asch, personal observation) may lead to binding of the adhesive macromolecule to GPIV on the platelet surface and serve as a site for further platelet-tumor cell interaction and substrate adhesion. We have previously demonstrated that TSP can bind plasminogen and modulate plasmin generation at a surface by tissue plasminogen activator (62) . Thus, TSP may support egress of malignant cells through basement membrane by localizing plasmin generation at the cell surface, or promote tumor cell adhesion by virtue of its lectinlike activity. TSP synthesis in smooth muscle cells and glial cells is regulated by platelet-derived growth factor (84) . Likewise, the TSP receptor, GPIV, may also be modulated by the cell cycle or growth factors.
The discovery of a shared cellular attachment sequence in fibrinogen, fibronectin, vitronectin, von Willebrand factor (28-36, 44, 45, 85) , and the implied existence ofa family ofreceptors (3) for these molecules suggests that they have broad biological importance. TSP also has a broad tissue distribution but differs from the other adhesion proteins in that it does not bind to GP lIB/IIIa (57) or like molecules (86) . Binding of TSP to the platelet surface has recently been shown to be independent of GPIIb/II~a (44 
